Cargando…
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60 months, median 24 months). Of these, 72 received endocrine therapy as first-line treatment for relapse. Immu...
Autores principales: | Wright, C., Nicholson, S., Angus, B., Sainsbury, J. R., Farndon, J., Cairns, J., Harris, A. L., Horne, C. H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977338/ https://www.ncbi.nlm.nih.gov/pubmed/1346366 |
Ejemplares similares
-
Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases.
por: Wright, C., et al.
Publicado: (1992) -
Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011) -
Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
por: Nicholson, S., et al.
Publicado: (1988) -
c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
por: Lovekin, C., et al.
Publicado: (1991) -
Expression of c-erbB-2 protein product in bladder cancer.
por: Wright, C., et al.
Publicado: (1990)